XHE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

XH

Volume

260.83K

Loading chart

XH

XHEState Street SPDR S&P Health Care Equipment ETF

XHE

Pay with—

Available Balance0.00

XH

AUM

N/A

Volume

260.83K

Yield

0.10%

Chart Earnings News About Dividends Insider Filings

Healthcare: Pockets of AlphaThe healthcare sector, down 3.8% year-to-date and the worst performer among S&P 500 sectors, presents selective opportunities despite weak aggregate earnings growth. While the sector faces headwinds with the lowest forward profit margins and weakest 2026 EPS growth outlook, specific subsectors show promise: Pharmaceuticals are rerating as GLP-1 economics mature, Biotech benefits from M&A activity, and smaller-cap healthcare companies outperform large-cap peers. The recommendation is a market-weight position focusing on areas with improving earnings, margins, and catalysts rather than broad sector exposure.Investing.com · Jun 23, 2026

Insulet Stock Hits 52-Week Low - Here's WhyInsulet Corp. (NASDAQ:PODD) shares fell to a 52-week low following the announcement of a voluntary Medical Device Correction for certain Omnipod 5 Pods. The manufacturing defect involves a small tear in internal tubing that delivers insulin, potentially causing under-delivery and serious health complications including diabetic ketoacidosis. The company has received 18 reports of serious adverse events. The affected pods represent approximately 1.5% of annual global production. Despite a Buy rating from analysts with a $356.64 price target, technical indicators show mixed momentum with the stock trading below key moving averages.Benzinga · Mar 13, 2026

FDA Expands Approval For Staar Surgical's Popular Implantable LensThe FDA approved an expanded age indication for Staar Surgical's EVO/EVO+ Visian Implantable Collamer Lenses, extending eligibility from ages 21-45 to 21-60 years old. This could add nearly 8 million refractive patients to the market. The approval is based on three-year clinical trial data showing strong safety profiles. Despite the positive news, the stock trades 9.8% below its 20-day moving average with bearish technical indicators, though RSI suggests oversold conditions.Benzinga · Feb 18, 2026

STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board InfluenceSTAAR Surgical shares declined as Broadwood Partners, which owns 31% of the company, gained board influence with two new directors joining alongside Christopher Wang of Yunqi Capital. The changes follow the failed merger with Alcon and include the departure of Chair Elizabeth Yeu, with CEO Stephen Farrell remaining until January 31, 2026. The stock is trading below key moving averages with mixed technical signals.Benzinga · Jan 15, 2026

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?Sector ETF report for XHEZacks Investment Research · Jun 24, 2024

Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says AnalystNeedham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112. The analyst says that Haemonetics has reaffirmed its “high-20%” FY26 operating margin goal. To reach this, the company must improve by approximately 600 basis points from its FY24 margin of 21.1%, writes the analyst. While the analyst earlier doubted the company’s ability to reach this target, the product mix analysis has bolstered their confidence. The analyst has identified two key factors influencing the company’s gross margin, which includes ...Full story available on Benzinga.comBenzinga · Jun 12, 2024

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?Sector ETF report for IHIZacks Investment Research · Jun 3, 2024

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?Smart Beta ETF report for XHEZacks Investment Research · May 10, 2024

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?Sector ETF report for XHEZacks Investment Research · Apr 22, 2024

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?Sector ETF report for IHIZacks Investment Research · Apr 3, 2024

to start trading

XH

XHEState Street SPDR S&P Health Care Equipment ETF

XHE

Pay with—

Available Balance0.00

Your PositionYou don't own any XHE yet.

Related Tickers

Earnings

Dividends

Last · Dec 22Quarterly

Amount$0.0220

Yield0.02%

Annual$0.0220